Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424762 · ClinicalTrials.gov registry record · Phase 4
Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00424762 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 150 participants.
The verdict
NCT00424762, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if rosiglitazone treatment improves integrated cardiovascular performance in patients at risk for congestive heart failure. A second aim of this study is to determine if treatment with rosiglitazone decreases intracellular (ectopic) triglyceride (TG) deposition in cardiomyocytes using nuclear magnetic resonance (NMR) techniques, and how changes in intra-myocardial lipid content relate to changes in cardiac structure and function.
Interventions
- DRUG placebo
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424762
The ClinicalTrials.gov registry entry for NCT00424762 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00424762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424762 about?
NCT00424762 is a clinical study titled "Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride". The purpose of this study is to determine if rosiglitazone treatment improves integrated cardiovascular performance in patients at risk for congestive heart failure. A second aim of this study is to determine if treatment with rosiglitazone decreases intracellular (ectopic) triglyceride (TG) deposit...
What is the current status of trial NCT00424762?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2005-02. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00424762?
The interventions under investigation include: placebo (DRUG), rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00424762?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.